These are four labels, not one class rule
Mounjaro and Zepbound are both tirzepatide. Ozempic and Wegovy are both semaglutide. The shared ingredient does not make the pregnancy or contraception text interchangeable. This page stays inside the current US prescribing information for those four brand names: Mounjaro revised 8/2026, Zepbound revised 8/2026, Ozempic revised 5/2026, and Wegovy revised 6/2026. The Wegovy label that was opened covers Wegovy injection and Wegovy tablets. Compounded products are outside this page. [1] [2] [3] [4]
Oral hormonal contraceptives
The useful split is not "GLP-1s and birth control." It is whether the opened label contains a specific oral-contraceptive instruction.
| Label topic | Mounjaro | Zepbound | Ozempic | Wegovy |
|---|---|---|---|---|
| Oral-contraceptive instruction | Section 8.3 says use may reduce the efficacy of oral hormonal contraceptives because of delayed gastric emptying. The delay is largest after the first dose and diminishes over time. The label says to advise a switch to a non-oral method, or an added barrier method, for 4 weeks after initiation and for 4 weeks after each dose escalation with Mounjaro. [1] | Section 8.3 says to advise the same step: switch to a non-oral method, or add a barrier method, for 4 weeks after initiation with Zepbound and for 4 weeks after each dose escalation. The stated reason is the same: delayed gastric emptying, largest after the first dose. [2] | No switch-or-barrier instruction appears in the label text opened for this page. Section 7.2 says clinical pharmacology trials found that semaglutide did not affect absorption of orally administered medications to any clinically relevant degree, and that caution should still be used. [3] | No switch-or-barrier instruction appears in the label text opened for this page. Section 7.2 says Wegovy delays gastric emptying and may affect absorption of oral medications. It also says semaglutide 1 mg once-weekly injection did not affect that absorption in clinical pharmacology trials. [4] |
| What was measured | After a single tirzepatide 5 mg dose, given with a combined oral contraceptive (0.035 mg ethinyl estradiol and 0.25 mg norgestimate), mean Cmax fell 59% for ethinyl estradiol, 66% for norgestimate, and 55% for norelgestromin. Mean AUC fell 20%, 21%, and 23%. Time to peak was delayed 2.5 to 4.5 hours. [1] | The same single-dose description and the same Cmax, AUC, and peak-time figures appear in the Zepbound pharmacokinetics section. The label does not call those reductions clinically irrelevant. It still gives the 4-week advice. [2] | Interaction trials were at semaglutide 1 mg steady-state exposure. Figure 4 includes an oral contraceptive (ethinylestradiol/levonorgestrel) assessed at steady state. The label says no clinically relevant interaction was observed for the evaluated medicines, so no dose adjustment of those medicines is required. The figure text does not print the percent changes. [3] | Under oral tablets, the label says no clinically significant pharmacokinetic difference was seen for ethinyl estradiol or levonorgestrel when used with semaglutide. That sentence is in the tablet section, not the injection section. The same tablet passage reports a 33% increase in levothyroxine exposure (90% CI 1.25–1.42), so a finding about one oral drug is not a finding about every oral drug. [4] |
| Non-oral hormonal methods | Section 7.2 says hormonal contraceptives that are not administered orally should not be affected. [1] | Section 7.2 uses that same sentence. [2] | The opened label does not make a separate oral-versus-non-oral contraceptive statement. [3] | The opened label does not make a separate oral-versus-non-oral contraceptive statement. [4] |
Both tirzepatide labels also say the impact on gastric emptying was greatest after a single 5 mg dose and diminished after subsequent doses. The contraceptive sentence itself is limited to 4 weeks after initiation and 4 weeks after each dose escalation. Reporting that sentence is not a dose to take and not a personal contraception plan. Whether the label's advice applies to a specific method is a question for the prescriber who knows the product and the contraceptive. [1] [2]
Recognized pregnancy and a planned pregnancy are different sentences
A contraception paragraph does not answer what a label says about pregnancy. Zepbound's reason for stopping in a recognized pregnancy is that weight loss offers no benefit and may cause fetal harm. Mounjaro and Ozempic use a benefit-risk sentence and describe risks of poorly controlled diabetes. Wegovy's wording depends on the labeled use, and the highlights do not match the full section word for word.
| Label topic | Mounjaro | Zepbound | Ozempic | Wegovy |
|---|---|---|---|---|
| If pregnancy is recognized | Does not say to discontinue when pregnancy is recognized. Section 8.1 says available human data are insufficient, that poorly controlled diabetes in pregnancy has maternal and fetal risks, and that Mounjaro should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Animal findings coincided with reductions in maternal body weights and food consumption. [1] | The label says to discontinue Zepbound when a pregnancy is recognized. Its reason: weight loss offers no benefit to a pregnant patient and may cause fetal harm. Human data are insufficient to evaluate a drug-related risk. Animal findings coincided with reductions in maternal body weight and food consumption. [2] | Does not say to discontinue when pregnancy is recognized. Section 8.1 says data in pregnant women are limited, describes risks of poorly controlled diabetes in pregnancy, and says Ozempic should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Animal findings coincided with marked maternal body-weight loss. [3] | Highlights say: for CV risk reduction or weight reduction, discontinue Wegovy when pregnancy is recognized; for MASH, use only if the potential benefit justifies the potential risk. The full section 8.1 says weight loss offers no benefit and may cause fetal harm, and says to discontinue Wegovy in pregnant patients using it for weight reduction. It uses a benefit-risk sentence for MASH with advanced liver fibrosis. Human data are insufficient to establish a drug-associated risk. [4] |
| Before a planned pregnancy | The opened label does not contain a "2 months before a planned pregnancy" instruction. [1] | The opened label does not contain a "2 months before a planned pregnancy" instruction. [2] | Section 8.3 says to discontinue Ozempic in women at least 2 months before a planned pregnancy because of the long washout period for semaglutide. Section 12.3 says the elimination half-life is approximately 1 week and semaglutide will be present in the circulation for about 5 weeks after the last dose. [3] | Section 8.3 says to discontinue Wegovy at least 2 months before a planned pregnancy because of the long half-life of semaglutide. The highlights limit that sentence to CV risk reduction, weight reduction, or MASH when the potential risk outweighs the potential benefit. Section 12.3 says the elimination half-life is approximately 1 week and semaglutide will be present for about 5 to 7 weeks after the last injectable dose of 2.4 mg or 7.2 mg, or an oral dose of 25 mg. [4] |
| Pregnancy registry named on the label | No pregnancy-exposure registry is named in the label text opened for this page. [1] | Yes. The label asks pregnant patients and clinicians to register at 1-844-524-0039, MILEregistry@thermofisher.com, or pregnancyregistry.lilly.com/zepbound. [2] | No pregnancy-exposure registry is named in the label text opened for this page. [3] | Yes. The label asks pregnant patients and clinicians to contact Novo Nordisk at 1-877-390-2760 or wegovypregnancyregistry.com. [4] |
Do not copy the Zepbound "discontinue when pregnancy is recognized" sentence onto Mounjaro, or the Ozempic 2-month sentence onto Zepbound. The Wegovy highlights and the full Wegovy section 8.1 are not worded identically; both are part of the label that was opened. None of these sentences is a decision this page can make. [1] [2] [3] [4]
What this page will not decide
It will not choose a contraceptive, interpret a pregnancy test, or tell anyone to start, stop, or time a dose. The 4-week and 2-month figures above are quotations from specific labels, not a schedule written for the person reading this. A missed dose, a switch between Wegovy injection and tablets, or a change in contraceptive method needs the prescriber and the current label for the exact product in hand.
Animal reproduction findings on these labels coincided with effects on maternal weight or food consumption. That does not turn an animal study into a human risk number, and the labels say the human pregnancy data are limited or insufficient. [1] [2] [3] [4]
Dates worth bringing to the prescriber
The Mounjaro and Zepbound oral-contraceptive sentences are anchored to two events: the day the medicine is started, and each day the dose is escalated. A prescriber can apply the label only if those dates, and the contraceptive actually in use, are written down. Blank and "unknown" are valid. Do not guess a date to fill a box. [1] [2]
CONTRACEPTION AND PREGNANCY LABEL PACKET
Exact product: Mounjaro / Zepbound / Ozempic / Wegovy injection /
Wegovy tablet / Unknown
Label revision printed on the source you have: ________ / Unknown
Use named by the prescriber: _________________________ / Unknown
Contraceptive in use, in the person's own words: ______ / Unknown
Is that method oral? Yes / No / Unknown
Is that method hormonal? Yes / No / Unknown
Date this exact product was started: _________________ / Unknown
Date of each dose escalation, if one happened:
1. ________________________________________________ / None recorded
2. ________________________________________________ / None recorded
3. ________________________________________________ / None recorded
Known pregnancy: Yes / No / Unknown
Planning a pregnancy has already been discussed: Yes / No / Unknown
UNANSWERED PRESCRIBER QUESTIONS
1. Which exact label section applies to this product and this use?
2. Does the oral-contraceptive sentence apply to the method listed above?
3. Which pregnancy sentence applies: recognized pregnancy, planned
pregnancy, or both?
4. Which original prescription and contraceptive record should be brought?
5. Other question: ___________________________________ / Unknown
This worksheet does not screen for pregnancy, pick a contraceptive, or interpret the label for a specific person. It keeps the facts the label sentences refer to.
The dates are the point
Keep the injection record that those label sentences use
The Jabbit App Store listing describes scheduling doses on daily, weekly, or custom patterns. That is a timing record, not a contraceptive decision. It does not choose a contraceptive or decide whether a medicine should stop.
Keep injection dates in JabbitFrequently asked questions
What do the Mounjaro and Zepbound labels say about oral hormonal contraceptives?
Both current labels say use may reduce the efficacy of oral hormonal contraceptives because of delayed gastric emptying. That delay is largest after the first dose and diminishes over time. Both tell clinicians to advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method for 4 weeks after initiation and for 4 weeks after each dose escalation. Both say hormonal contraceptives that are not administered orally should not be affected. [1] [2]
Do the Ozempic and Wegovy labels give that same 4-week instruction?
No. The Ozempic and Wegovy labels opened for this page do not tell clinicians to switch contraceptive methods or add a barrier method. Ozempic says semaglutide did not affect absorption of orally administered medications to any clinically relevant degree in clinical pharmacology trials, and still says to use caution with oral medications. Its pharmacokinetics section says no clinically relevant interaction was observed for the evaluated medicines, including an oral contraceptive assessed at steady state, at semaglutide 1 mg steady-state exposure. Wegovy says it delays gastric emptying and may affect oral medications. It reports that semaglutide 1 mg once-weekly injection did not affect absorption of orally administered medications, and that the oral-tablet studies found no clinically significant pharmacokinetic difference for ethinyl estradiol or levonorgestrel. [3] [4]
What do the labels say if a pregnancy is recognized?
Zepbound says to discontinue Zepbound when a pregnancy is recognized, because weight loss offers no benefit to a pregnant patient and may cause fetal harm. Mounjaro and Ozempic do not use that sentence. Each says to use the medicine during pregnancy only if the potential benefit justifies the potential risk to the fetus, and each describes risks of poorly controlled diabetes in pregnancy. Wegovy's highlights say to discontinue Wegovy when pregnancy is recognized for CV risk reduction or weight reduction, and to use a benefit-risk standard for MASH. The full Wegovy pregnancy section says to discontinue Wegovy in pregnant patients using it for weight reduction. [1] [2] [3] [4]
What do the labels say about a planned pregnancy?
Ozempic says to discontinue Ozempic in women at least 2 months before a planned pregnancy because of semaglutide's long washout. Wegovy says to discontinue Wegovy at least 2 months before a planned pregnancy because of semaglutide's long half-life. The highlights add an indication qualifier that the full section 8.3 sentence does not. The Mounjaro and Zepbound labels opened for this page do not contain a 2-month pre-pregnancy instruction. Timing still belongs with the prescriber and the current label for the exact product. [1] [2] [3] [4]
What is worth writing down before that conversation?
The tirzepatide labels attach the oral-contraceptive advice to the start of treatment and to each dose escalation. A useful record is the exact product, the dates those events happened, and whether the contraceptive in use is oral. Jabbit's listing describes dose scheduling. It does not choose a contraceptive or decide whether to stop a medicine. [1] [2]
Sources opened and checked
- [1]Mounjaro US prescribing information, DailyMed, revised 8/2026: sections 7.2, 8.1, 8.3, and 12.3.
- [2]Zepbound US prescribing information, DailyMed, revised 8/2026: highlights, sections 7.2, 8.1, 8.3, and 12.3.
- [3]Ozempic US prescribing information, DailyMed, revised 5/2026: sections 7.2, 8.1, 8.3, and 12.3.
- [4]Wegovy US prescribing information, DailyMed, revised 6/2026: highlights, sections 7.2, 8.1, 8.3, and 12.3.
All four labels were opened and checked October 15, 2026. Registry links are the ones printed on those labels.